4 days ago · “With Biogen’s deep experience in neurology and track record of success in commercializing high-value disease-modifying medicines for rare genetic diseases globally, we aim to lead the treatment of Dravet syndrome into a new era by delivering zorevunersen to all patients who could benefit,” said Edward M. Kaye, M.D., Chief Executive ...

2 days ago · Biogen and Stoke Therapeutics entered a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the U.S., Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of ...

3 days ago · Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome is a genetic developmental and epileptic encephalopathy characterised by cognitive and behavioural impairments and recurrent seizures.

1 day ago · “With Biogen’s deep experience in neurology and track record of success in commercializing high-value disease-modifying medicines for rare genetic diseases globally, we aim to lead the treatment of Dravet syndrome into a new era by delivering zorevunersen to all patients who could benefit,” said Edward M. Kaye, MD, CEO, Stoke Therapeutics ...

4 days ago · Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

4 days ago · By Biogen’s estimates, Dravet syndrome affects up to 38,000 people in the U.S., U.K., Japan and several European countries. Zorevunersen is a type of genetic medicine known as an antisense oligonucleotide. It’s designed to bind to select sequences of RNA to increase the expression of a sodium channel protein tied to Dravet Syndrome.

3 days ago · The companies said Biogen will also chip in 30% of external clinical development costs for zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a genetic ...

3 days ago · Biogen’s leadership has said they aren’t eager to deal, but turns out Stoke Therapeutics had a little something in its rare disease catalog that prompted Biogen to strike.The companies will work on a Dravet syndrome treatment under a deal worth $165 million upfront. Stoke is also eligible for $385 million in total payments in development and commercial milestones, plus royalties on future ...

2 days ago · “With Biogen’s deep experience in neurology and track record of success in commercializing high-value disease-modifying medicines for rare genetic diseases globally, we aim to lead the treatment of Dravet syndrome into a new era by delivering zorevunersen to all patients who could benefit,” said Edward M. Kaye, M.D., Chief Executive ...

1 day ago · Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and Japan are estimated to be living with Dravet syndrome, a genetic developmental and epileptic ...